Navigation Links
Sangamo BioSciences Reports First Quarter 2013 Financial Results
Date:5/8/2013

e statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited)Statement of Operations Data: Three Months Ended March 31, 20132012Revenues:  Collaboration agreements

$
4,083$
,663  Research grants

5401,579Total revenues

4,6233,242Operating expenses:Research and development

8,2207,283General and administrative

3,3083,242Total operating expenses

11,52810,525Loss from operations

(6,905)(7,283)Interest and other income, net

2015Net loss

$
(6,885)$
(7,268)Basic and diluted net loss per common share

$
(0.13)$
(0.14)Shares used in computing basic and diluted net loss per

common share53,37752,567March 31, 2013December 31, 2012(Unaudited)Selected Balance Sheet D
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
10. Neurocrine Biosciences Reports First Quarter 2012 Results
11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 16 BioVex Inc, a biotechnology,company developing clinical ... that the abstract describing the interim results,from its ... advanced metastatic,melanoma is now available at the American ... http://www.asco.org . A summary of the abstract,which describes ...
... Nektar,s Technology Enables First-Ever PEGylation of a Small Molecule with ... Demonstrated Therapeutic ... NKTR ) announced initial results today from a Phase ... activity in patients with refractory solid tumors. The study,also demonstrates ...
Cached Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... a kind of disability. Researchers at Pope University, have found ... of aged people between 51 and 62.// ,Those ... cent more likely to report disabilities with respect to work ... greater risk. These were people who drank more than three ...
... aspirin because it thins the blood and prevents the ... widely used class of pain relievers known as nonsteroidal ... other aches and pains. The popular pain reliever ibuprofen ... study that sounds a warning for people who take ...
... are infected with HIV every year in the US, with ... of all U.S. patients with the AIDS virus have an ... to treat it. // Drug-resistant HIV had spread faster and ... normal lives were becoming increasingly limited in their usefulness. ...
... offer some protection against adult-onset diabetes.,An expert behind the ... benefit now by adding the spice to their food.// ... more prevalent than insulin-dependent diabetes, which normally begins earlier ... and insulin injections. It happens when cells in the ...
... is responsible for people who find it impossible to stay ... new treatments for jet lag//, insomnia and seasonal depression. ... cannot stay awake much after 8.30pm and who wake up ... advanced sleep-phase syndrome". This means the person's body clock is ...
... they have discovered the Holy Grail of bad smells ... effects of flatulence. American researchers believe the answer to ... that an object called a Toot Trapper, a cushion ... to almost unnoticeable levels. ,The scientists from ...
Cached Medicine News:Health News:Sniff out flatulence, 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: